Rubraca (rucaparib) — CareFirst (Caremark)
Pancreatic adenocarcinoma
Initial criteria
- Tumor has BRCA‑mutations (germline or somatic) or PALB2‑mutations
- Disease has not progressed on at least 16 weeks of a platinum-based chemotherapy
- Medication will be used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months